Figure 7. IT-139 treatment in vivo.

(A) HCT116 xenograft tumors were treated with saline control, oxaliplatin, or IT-139 in combination with oxaliplatin at 2 doses. Oxaliplatin in combination with IT-139 at 50 mg/kg had significant anti-tumor efficacy, but this group saw the most weight loss. No animal in this group experienced weight loss exceeding 20% of weight at study start. (B) A549 xenograft tumors were treated with saline control, cisplatin or IT-139 in combination with cisplatin at 2 doses. Both combination groups saw significant efficacy over the cisplatin treated and control treated groups. The most weight loss was seen in the higher dosed combination group. (C) HT-29 xenograft tumor models were treated with saline control, IT-139 alone or in combination with 5-FU at 50 mg/kg. IT-139 was seen to have an effect in both the monotherapy and combination therapy groups. HT-29 cells are 5-FU resistant as observed by the rate of tumor growth in the 5-FU treated group. Although an initial weight loss was seen in the combination group, all treated animals showed normal weight gain in the study. No treated animals in the three xenograft studies experienced weight loss exceeding 20% of weight at study start.